(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/008469 A1

(51) International Patent Classification:
A61K 31/404 (2006.01) *A61K 31/506* (2006.01)
A61K 31/416 (2006.01) *A61K 31/517* (2006.01)
A61K 31/44 (2006.01) *A61K 31/53* (2006.01)
A61K 31/443 (2006.01) *A61K 39/00* (2006.01)
A61K 31/444 (2006.01) *A61K 39/395* (2006.01)
A61K 31/47 (2006.01) *A61P 35/02* (2006.01)
A61K 31/5025 (2006.01)

(21) International Application Number:
PCT/EP2021/068564

(22) International Filing Date:
06 July 2021 (06.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20184962.7 09 July 2020 (09.07.2020) EP

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors: **FRIESE-HAMIM, Manja**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE). **ROHDICH, Felix**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE). **GIMMI, Claude**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE). **SCHULTES, Christoph**; c/o Merck A.E., 41 - 45 Kifisias Ave, 15123 MAROUSSI (GR). **BOGATYROVA, Olga**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/008469 A1

(54) Title: COMBINATION OF A METHIONINE AMINOPEPTIDASE 2 INHIBITOR AND VEGFR/VEGF INHIBITOR

(57) Abstract: The invention relates to combinations of (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo- pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide and a VEGFR/VEGF inhibitor, or their physiologically acceptable salts, as well as to the use of such combinations for the prophylaxis or treatment of cancer.